Clinical outcomes in patients (pts) with a history of central nervous   system (CNS) metastases receiving talazoparib (TALA) or physician's   choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.

Dokumenttyp:: Meeting Abstract
Autor(en):: Litton, Jennifer Keating; Ettl, Johannes; Hurvitz, Sara A.; Martin, Miguel; Roche, Henri; Lee, Kyung-Hun; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Guenzel, Carolin; Blum, Joanne Lorraine; Rugo, Hope S.
Titel:: Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.
Zeitschriftentitel:: J Clin Oncol
Jahr:: 2021
Band / Volume:: 39 Suppl S
Heft / Issue:: 15
Volltext / DOI:: doi:10.1200/JCO.2021.39.15_suppl.1090
Print-ISSN:: 0732-183X
TUM Einrichtung:: Frauenklinik und Poliklinik
BibTeX

Vorkommen: